Unveiling the Story Behind Biomarin Pharmaceutical BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi ...

Product revenues (including Aldurazyme) totaled $586.4 million, up 16% year over year. The same from BioMarin's marketed brands (excluding Aldurazyme) increased 15% year over year to $552 million ...

The estimate indicates a year-over-year change of -36.6%. The consensus estimate for 'Revenues- Net Product Revenues- ALDURAZYME' stands at $32.79 million. The estimate suggests a change of -4.7% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the quarter ended March 31, 2024.

BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.